

Pavlos Msaouel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/720497/publications.pdf>

Version: 2024-02-01

113
papers

2,635
citations

236925

25
h-index

233421

45
g-index

118
all docs

118
docs citations

118
times ranked

3967
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of the insulin-like growth factor-1 system in breast cancer. <i>Molecular Cancer</i> , 2015, 14, 43.	19.2	287
2	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	30.7	193
3	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. <i>Current Cancer Drug Targets</i> , 2018, 18, 177-187.	1.6	107
4	Mechanisms of bone metastasis in prostate cancer: clinical implications. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 341-355.	4.7	93
5	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1732-1739.	10.7	84
6	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	16.8	74
7	Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. <i>BMC Cancer</i> , 2011, 11, 336.	2.6	69
8	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	16.8	62
9	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. <i>Oncologist</i> , 2020, 25, 252-258.	3.7	62
10	Oncolytic measles virus strains as novel anticancer agents. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 483-502.	3.1	60
11	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	1.9	60
12	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. <i>European Journal of Cancer</i> , 2018, 104, 188-194.	2.8	58
13	A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2044-2049.	7.0	56
14	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. <i>Journal of Urology</i> , 2017, 198, 530-537.	0.4	55
15	An Evidence-Based Determination of Issues Affecting Quality of Life and Patient-Reported Outcomes in Lung Cancer: Results of a Survey of 660 Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1243-1248.	1.1	52
16	Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.	2.5	52
17	Burnout and training satisfaction of medical residents in Greece: will the European Work Time Directive make a difference?. <i>Human Resources for Health</i> , 2010, 8, 16.	3.1	45
18	Greek medical students'™ career choices indicate strong tendency towards specialization and training abroad. <i>Health Policy</i> , 2006, 79, 101-106.	3.0	43

#	ARTICLE	IF	CITATIONS
19	Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. <i>JAMA Network Open</i> , 2021, 4, e2036321.	5.9	39
20	Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e447-e453.	1.9	34
21	Outcomes in World Health Organization Group II Pulmonary Hypertension: Mortality and Readmission Trends With Systolic and Preserved Ejection Fraction-Induced Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, 467-475.	1.7	32
22	Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 103-116.	1.9	31
23	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	17.5	31
24	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 89-93.	2.5	30
25	Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1297-1316.	4.1	29
26	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. <i>Science Translational Medicine</i> , 2022, 14, eabm6420.	12.4	29
27	Assessment of cognitive biases and biostatistics knowledge of medical residents: a multicenter, cross-sectional questionnaire study. <i>Medical Education Online</i> , 2014, 19, 23646.	2.6	28
28	Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 679-686.	2.5	28
29	The Effort-Reward Imbalance Questionnaire in Greek: Translation, Validation and Psychometric Properties in Health Professionals. <i>Journal of Occupational Health</i> , 2012, 54, 119-130.	2.1	26
30	Causal Diagram Techniques for Urologic Oncology Research. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 271.e1-271.e7.	1.9	25
31	Thrombocytopaenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction. <i>Heart Lung and Circulation</i> , 2016, 25, 568-575.	0.4	23
32	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100166.	1.7	23
33	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. <i>Cancers</i> , 2021, 13, 2741.	3.7	23
34	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	12.8	23
35	Methods of detection of circulating melanoma cells: A comparative overview. <i>Cancer Treatment Reviews</i> , 2011, 37, 284-290.	7.7	22
36	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , 2021, 81, 332-343.	0.9	22

#	ARTICLE	IF	CITATIONS
37	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	2.5	22
38	Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1488-94.	2.3	21
39	Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 285-299.	2.4	19
40	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. <i>Oncologist</i> , 2021, 26, 476-482.	3.7	19
41	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
42	A cytoskeletal function for PBRM1 reading methylated microtubules. <i>Science Advances</i> , 2021, 7, .	10.3	17
43	TAM kinase inhibition and immune checkpoint blockade – a winning combination in cancer treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 141-151.	3.4	17
44	Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 569-573.	1.6	16
45	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020, 16, e1264-e1271.	2.9	16
46	The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer. <i>Anticancer Research</i> , 2015, 35, 819-26.	1.1	16
47	The Big Data Paradox in Clinical Practice. <i>Cancer Investigation</i> , 2022, 40, 567-576.	1.3	16
48	Combination antiangiogenic tyrosine kinase inhibition and anti- PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	2.8	15
49	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , 2021, 13, 2170.	3.7	15
50	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
51	Precision Bayesian phase I dose-finding based on utilities tailored to prognostic subgroups. <i>Statistics in Medicine</i> , 2021, 40, 5199-5217.	1.6	15
52	Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. <i>Oncotarget</i> , 2019, 10, 3979-3981.	1.8	15
53	Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. <i>European Urology Oncology</i> , 2020, 3, 687-694.	5.4	14
54	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e401-e408.	1.9	14

#	ARTICLE	IF	CITATIONS
55	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. <i>Cancers</i> , 2021, 13, 6022.	3.7	14
56	Primary Urinary Tract Lymphoma: Rare but Aggressive. <i>Anticancer Research</i> , 2017, 37, 6989-6995.	1.1	13
57	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e2122998.	5.9	13
58	Review: The Role of Insulin-like Growth Factor-1 Signaling Pathways in Uterine Leiomyoma. <i>In Vivo</i> , 2015, 29, 637-49.	1.3	13
59	Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1385-1400.	4.1	12
60	Immune Checkpoint Therapy in Head and Neck Cancers. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 108-116.	2.0	12
61	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e47-e57.	1.9	12
62	Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. <i>Anticancer Research</i> , 2014, 34, 7415-24.	1.1	12
63	Causal considerations can inform the interpretation of surprising associations in medical registries. <i>Cancer Investigation</i> , 2021, , 1-27.	1.3	11
64	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.	5.4	11
65	Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. <i>Heart and Vessels</i> , 2017, 32, 969-976.	1.2	10
66	Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1777060.	0.7	10
67	Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials. <i>Cancer Investigation</i> , 2021, 39, 1-6.	1.3	10
68	A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma. <i>Oxford Medical Case Reports</i> , 2015, 2015, 343-345.	0.4	9
69	Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 315-318.	1.9	9
70	Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 134.e9-134.e16.	1.6	9
71	Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Cancers</i> , 2021, 13, 695.	3.7	9
72	A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 312-312.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	3.4	7
74	A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 612-612.	1.6	7
75	Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211031.	3.2	7
76	Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 276-289.	2.1	6
77	The evolving treatment landscape of advanced urothelial carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 221-230.	2.4	6
78	Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021, 149, 387-393.	5.1	6
79	Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. <i>European Urology Oncology</i> , 2022, 5, 265-267.	5.4	6
80	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 42149-42158.	1.8	6
81	A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. <i>Statistics in Medicine</i> , 2020, 39, 2035-2050.	1.6	5
82	Primary Hepatic Small Cell Carcinoma: Two Case Reports, Molecular Characterization and Pooled Analysis of Known Clinical Data. <i>Anticancer Research</i> , 2016, 36, 271-7.	1.1	5
83	Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). <i>BMJ Supportive and Palliative Care</i> , 2017, 7, bmjspcare-2016-001146.	1.6	4
84	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 654-654.	1.6	4
85	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. <i>Cancer Investigation</i> , 2022, 40, 184-188.	1.3	4
86	Medicine before and after David Cox. <i>European Journal of Internal Medicine</i> , 2022, 98, 1-3.	2.2	4
87	Recent developments in the management of germ cell tumors. <i>Current Opinion in Oncology</i> , 2017, 29, 172-178.	2.4	3
88	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. <i>Cancers</i> , 2020, 12, 710.	3.7	3
89	Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100349.	1.7	3
90	Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. <i>Oncotarget</i> , 2016, 7, 67948-67955.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. <i>Anticancer Research</i> , 2020, 40, 6213-6219.	1.1	3
92	The Independent Effect of Platelet Count On Mortality in a Large Inner City Elderly Outpatient Population. <i>Blood</i> , 2012, 120, 4645-4645.	1.4	3
93	Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples. <i>Anticancer Research</i> , 2014, 34, 2937-42.	1.1	3
94	Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-356.	1.6	3
95	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 311-326.	3.8	3
96	Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e73-e77.	1.9	2
97	Metabolic Derangements in Succinate Dehydrogenase Bâ€™Mutated Renal-Cell Carcinomas: More Than Meets the Eye?. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	3.0	2
98	Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 709-718.	1.1	2
99	Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 324-324.	1.6	2
100	Improving clinical prognostic categories beyond performance status: Enhancing accuracy in survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in lung cancer and mesothelioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8065-8065.	1.6	2
101	Research update for articles published in <i>EJCI</i> in 2012. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1010-1023.	3.4	1
102	Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. <i>European Urology</i> , 2017, 71, 415-416.	1.9	1
103	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e001073.	4.5	1
104	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	1.9	1
105	Multiplicative Interaction Between Mean Corpuscular Volume and Red Cell Distribution Width in Predicting Mortality of Elderly Patients with and without Anemia. <i>Blood</i> , 2012, 120, 5150-5150.	1.4	1
106	Management of Non-Clear Cell Renal Cell Carcinoma. , 2020, , 307-323.		1
107	Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 351-351.	1.6	1
108	Continuing Medical Education Activity in <i>Echocardiography</i>. <i>Echocardiography</i> , 2014, 31, 751-751.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: A systematic review and individual patient data meta-analysis.. Journal of Clinical Oncology, 2021, 39, 317-317.	1.6	0
110	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. Journal of Clinical Oncology, 2021, 39, 406-406.	1.6	0
111	Abstract W MP65: Accuracy of Two-Dimensional Echocardiography using Second Harmonic Imaging for the Diagnosis of Intracardiac Right-to-Left Shunt: A Meta-Analysis of Prospective Studies. Stroke, 2014, 45, .	2.0	0
112	Medical and socioeconomic factors associated with triple-negative breast cancer (TNBC) in women with health care disparities.. Journal of Clinical Oncology, 2014, 32, e17512-e17512.	1.6	0
113	Truncating mutations: an insight into the biology of urinary tract carcinomas?. American Journal of Cancer Research, 2021, 11, 6214-6217.	1.4	0